# Avacta Group launch of SARS-CoV-2 BAMS research test

- Link: https://www.directorstalkinterviews.com/avacta-group-launch-of-sars-cov-2-bams-research-test/412861965
- Published: 2020-09-30T13:43:45+01:00
- Author: Amilia Stone

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l)),
the developer of innovative cancer therapies and diagnostics based on its proprietary
Affimer® and pre|CISION^(TM) platforms, has announced that the BAMS assay to detect
the SARS-CoV-2 virus has been launched as a research kit^(1) by its partner Adeptrix(
Beverly, MA, USA) and the assay has been presented by Bruker Scientific (Billerica,
MA, USA), a leading mass spectrometer manufacturer, in a new application note^(2).

The bead-assisted mass spectrometry assay uses the Affimer reagents specific to 
the SARS-CoV-2 virus to capture the virus spike protein from the sample for rapid
detection by mass spectrometry, using the installed base of these instruments in
hospitals. Up to one thousand samples per day can be analysed by a single technician
using BAMS, making BAMS a very attractive high throughput technique for COVID-19
diagnosis and research.

Adeptrix has launched a BAMS research assay kit incorporating Avacta’s Affimer reagents
in order to make this powerful tool available to researchers globally to support
the fight against the coronavirus. Work carried out in parallel by Bruker, a leading
mass spectrometer manufacturer with a significant installed base of instruments 
in hospitals globally, to assess the performance of the assay has been published
by Bruker in a detailed application note.

Avacta continues to work actively with the UK government’s CONDOR programme to clinically
evaluate the coronavirus BAMS assay in order to obtain regulatory approval for diagnostic
use. Avacta and Adeptrix are in discussions with mass spectrometer manufacturers
with a view to establishing commercial partnerships to market the research use and
diagnostic products.

Commercial details are not being disclosed but Avacta will receive a royalty on 
the SARS-CoV-2 BAMS research kit sales.

1. https://adeptrix.com/store#!/SARS-CoV-2-S1-GlycoproteinAssay/p/234586062/category
=0 

2. https://www.bruker.com/fileadmin/user_upload/8-PDF-Docs/Separations_MassSpectrometry/
Literature/ApplicationNotes/1881181_MT-128_SARS-CoV-2_Antigen_Assay_ebook.pdf

> **Alastair Smith, Chief Executive Officer of Avacta Group, commented:**
> “I am delighted that the Affimer-based BAMS assay developed with Adeptrix is now
> available for scientists to use in their research into the coronavirus. A research
> use assay is the first step in commercialising this powerful Affimer-based coronavirus
> research and diagnostic tool and the clinical evaluation of the assay in the UK
> to support CE marking for diagnostic use is a very high priority for Avacta.
> I am also very pleased indeed that Bruker has published their application note,
> providing considerable detail about the performance of the SARS-CoV-2 BAMS assay,
> clearly demonstrating the potential of this Affimer-based coronavirus mass spectrometry
> test and another important validation of the Affimer platform.
> I look forward to updating the market on the clinical evaluation of the BAMS assay
> and on commercial progress in due course.”

Share on:
